PD Dr. med. Arnoud Templeton

Stv. Leitung St. Clara Forschung
Leiter Forschungsgruppe Onkologie/Medizin
Leitender Arzt

Portrait  PD Dr. med. Arnoud Templeton

Seit 2023

Stv. Leitung St. Clara Forschung AG

Seit 2020

Gruppenleiter onkologische und allgemeine Forschung St. Clara Forschung AG 

Seit 2017

Leitender Arzt St. Claraspital Basel


Oberarzt, St. Claraspital Basel


Habilitation, Privatdozent, Onkologie, Universität Basel

2016 - 2017    

Oberarzt Onkologie St. Claraspital Basel

2014 – 2016    

Oberarzt Kantonsspital St. Gallen, Switzerland

2012 – 2014    

Klinischer Forschungsstipendiat Princess Margaret Cancer Centre, Toronto, Kanada

2010 – 2012

Medizinischer Berater der SAKK (Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung), Bern


Facharzt für Onkologie, FMH (Berufsverband der Schweizer Ärztinnen und Ärzte)


European Society of Medical Oncology (ESMO) Exam


Facharzt für Innere Medizin, FMH (Berufsverband der Schweizer Ärztinnen und Ärzte)

2003 – 2010

Facharztausbildung für Innere Medizin (Zofingen und St. Gallen), Infektiologie (St. Gallen), Onkologie (St. Gallen)


Doktorarbeit (über ein MD Programm), Medizinische Fakultät, Universität Basel


Eidgenössische Prüfung in Humanmedizin, Universität Basel

1995 - 2002    

Medizinstudium, Universität Basel (1 Jahr Austauschprogramm an der Medizinischen Fakultät der Technischen Universität (TU), Dresden 

  • Swiss Federal Medical Association (FMH)
  • European Society of Medical Oncology (ESMO)
  • Swiss Society of Medical Oncology (SGMO)
  • Neubauer MC, Nicolas GP, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, Forrer F, Rentsch C, Stenner F, Templeton A, Schäfer N, Wild D, Chirindel A; all investigators on behalf of the SSNM Therapy Working Group. Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1185-1193. DOI: 10.1007/s00259-023-06536-2. Epub 2023 Dec 1.
  • Bratic Hench I, Roma L, Conticelli F, Bubendorf L, Calgua B, Le Magnen C, Piscuoglio S, Rubin MA, Chirindel A, Nicolas GP, Vlajnic T, Zellweger T, Templeton AJ, Stenner F, Ruiz C, Rentsch C, Bubendorf L. Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer. Cancers (Basel). 2023 Dec 21;16(1):45. DOI: 10.3390/cancers16010045
  • Kudura K, Ritz N, Templeton AJ, Kutzker T, Hoffmann MHK, Antwi K, Zwahlen DR, Kreissl MC, Foerster R. An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data. Cancers (Basel). 2023 Nov 20;15(22):5476. DOI: 10.3390/cancers15225476
  • Kovač MB, Pavlin T, Čavka L, Ribnikar D, Spazzapan S, Templeton AJ, Šeruga B. The trajectory of sarcopenia following diagnosis of prostate cancer: A systematic review and meta-analysis. J Geriatr Oncol. 2023 Sep;14(7):101594. DOI: 10.1016/j.jgo.2023.101594. Epub 2023 Jul 22.
  • Templeton AJ, Omlin A, Berthold D, Beyer J, Burger IA, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schaefer N, Seiler D, Stenner F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. Swiss Med Wkly. 2023 Aug 15;153:40108. DOI: 10.57187/smw.2023.40108.
  • Pandiella A, Calvo E, Moreno V, Amir E, Templeton A, Ocana A. Considerations for the clinical development of immuno-oncology agents in cancer. Front Immunol. 2023 Aug 11;14:1229575. DOI: 10.3389/fimmu.2023.1229575
  • Kudura K, Ritz N, Templeton AJ, Kutzker T, Foerster R, Antwi K, Kreissl MC, Hoffmann MHK. Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition. J Clin Med. 2023 May 28;12(11):3725. DOI: 10.3390/jcm12113725
  • Schlegel T, Haegele-Link S, Bertotto C, Rieger U, Wittchow S, Schlaeppi M, Templeton A. Diagnosis and Treatment of Patients Utilizing Complementary Medicine at a Tertiary Referral Hospital in Eastern Switzerland. Complement Med Res. 2023 May 16. DOI: 10.1159/000531071. Epub ahead of print.
  • Kudura K, Ritz N, Templeton AJ, Kissling M, Kutzker T, Foerster R, Hoffmann MHK, Antwi K, Kreissl MC. Additional Primary Tumors Detected Incidentally on FDG PET/CT at Staging in Patients with First Diagnosis of NSCLC: Frequency, Impact on Patient Management and Survival. Cancers (Basel). 2023 Feb 28;15(5):1521. DOI: 10.3390/cancers15051521
  • Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller B, Fankhauser CD, Hirschi-Blickenstorfer A, Seifert B, Kluth LA, Ufe MP, Mingrone W, Templeton AJ, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci. 2023 Feb 20;50:57-60. DOI: 10.1016/j.euros.2023.01.013
  • Kudura K, Ritz N, Kutzker T, Hoffmann MHK, Templeton AJ, Foerster R, Kreissl MC, Antwi K. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. Cancers (Basel). 2022 Dec 11;14(24):6095. DOI: 10.3390/cancers14246095
  • Christiansen AJ, Lobo J, Fankhauser CD, Rothermundt C, Cathomas R, Batavia AA, Grogg JB, Templeton AJ, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence. Front Oncol. 2022 Dec 8;12:1056823. DOI: 10.3389/fonc.2022.1056823.
  • Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton AJ, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser CD. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus. 2022 Nov 12:S2405-4569(22)00246-2. DOI: 10.1016/j.euf.2022.11.003. Epub ahead of print.
  • Bojaxhiu B, Sinovcic D, Elicin O, Templeton AJ, Shelan M, Wartenberg J, Alberts I, Rominger A, Aebersold DM, Zaugg K. Correlation between hematological parameters and PET/CT metabolic parameters in patients with head and neck cancer. Radiat Oncol. 2022 Aug 13;17(1):141. DOI: 10.1186/s13014-022-02112-4
  • Adam R, Tibau A, Molto Valiente C, Šeruga B, Ocaña A, Amir E, Templeton AJ. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PLoS One. 2022 Jun 10;17(6):e0268545. DOI: 10.1371/journal.pone.0268545
  • Pratsinis M, Fankhauser C, Pratsinis K, Beyer J, Bührer E, Cathomas R, Fischer N, Hermanns T, Hirschi-Blickenstorfer A, Kamradt J, Alex Kluth L, Zihler D, Mingrone W, Müller B, Nestler T, Rothschild SI, Seifert B, Templeton AJ, Terbuch A, Ufen MP, Woelky R, Gillessen S, Rothermundt C. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. Eur Urol Open Sci. 2022 Apr 26;40:16-18. DOI: 10.1016/j.euros.2022.03.013
  • Schmid T, Templeton A: Moderne Therapie des fortgeschrittenen Prostatakarzinoms. 2021: Schweizer Zeitschrift für Onkologie SZO 1: 10–18.
  • Fankhauser CD, Christiansen AJ, Rothermundt C, Cathomas R, Wettstein MS, Grossmann NC, Grogg JB, Templeton AJ, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer. 2021 Dec 15. doi: 10.1038/s41416-021-01643-z.dd. IF 7.640 (JCI 2020; rank 39/242 oncology)
  • Bujosa A, Moltó C, Hwang TJ, Tapia JC, Vokinger KN, Templeton AJ, Gich I, Barnadas A, Amir E, Tibau A.  Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period. J Natl Compr Canc Netw 2021 Sep 24;1-9. doi: 10.6004/jnccn.2021.7003. IF 11.903 (JCI 2020; rank 21/242 oncology)
  • Servant R, Garioni M, Vlajnic T, Blind M, Pueschel H, Müller DC, Zellweger T, Templeton AJ, Garofoli A, Maletti S, Piscuoglio S, Rubin MA, Seifert H, Rentsch CA, Bubendorf L, Le Magnen C. Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. J Pathol 2021 doi: 10.1002/path.5698. IF 6.021 (JCI 2019; rank 40/244 oncology, 5/78 pathology)
  • Ribnikar D, Goldvaser H, Veitch ZW, Ocana A, Templeton AJ, Šeruga B, Amir E. Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade. Sci Rep 2021 May 25;11(1):10843. doi: 10.1038/s41598-021-90403-3. IF 4.380 (JCI 2020; rank 17/72 multidisciplinary sciences)
  • Templeton AJ, Booth CM, Tannock IF.  Informing Patients about Expected Outcomes: The Efficacy-Effectiveness Gap. J Clin Oncol. 2020 May 20;38(15):1651-1654. doi: 10.1200/JCO.19.02035
  • Templeton AJ, Amram M-L, Berthold D, Beyer J, Samuel Blaser S, Burger I, Eberli D, Gillessen S, Grobholz R, Küng M, Mattei A, Omlin A, Papachristofilou A, Rentsch C, Schefer N, Schmid H-P, Spahn M, Stenner F, Thalmann G, Wyler S, Zilli T, Cathomas R. Interdisziplinäre schweizerische Konsensempfehlungen zur Behandlung des fortgeschrittenen Prostatakarzinoms. Swiss Med Forum. 2020;20(4950):718-723.
  • Templeton AJ, Amir E, Tannock IF. Informative censoring – a neglected cause of bias in oncology trials. Nat Rev Clin Oncol. 2020 Jun;17(6):327-328. doi: 10.1038/s41571-020-0368-0.
  • Templeton AJ, Schmid T. Wenn Information zensiert wird. Info@Onkologie. 2020; 6: 28-30.
  • Tannock IF, Templeton AJ.  Flawed Trials for Cancer. Ann Oncol. 2020 Mar;31(3):331-333. doi: 10.1016/j.annonc.2019.11.017.
  • Schmid T, Templeton AJ. Wenn mein Patient kein Studienpatient ist: Efficacy-Effectiveness Gap. Info@Onkologie. 2020; 04: 23-24.
  • Tapia JC, Molto C, Bujosa A, Templeton AJ, Barnadas A, Amir E, Tibau A. Associations with Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Approval and in the Post-marketing Period. Journal of the National Comprehensive Cancer Network 2020 [in press].
  • Ribnikar D, Goldvaser H Veitch ZW, Ocana A, Templeton AJ, Seruga B, Amir E. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. Cancer Med. 2020 Nov;9(21):7888-7895. doi: 10.1002/cam4.3390.
  • Wallrabenstein T, del Rio J, Templeton AJ, Buess MA. Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer. PLoS One 2020 May 29;15(5):e0233768. doi: 10.1371/journal.pone.0233768.
  • Fehr M, Hawle H, Hayoz S, Thuss-Patience P, Schacher S, Knorrenschild JR, Dürr D, Knoefel WT, Rumpold H, Bitzer M, Zweifel M, Samaras P, Mey U, Küng M, Winterhalden R, Eisterer W, Hess V, Gerard M-A, Templeton AJ, Stahl M, Ruhstaller T. High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08. BMC Cancer. 2020 Feb 28;20(1):166. doi: 10.1186/s12885-020-6623-z.
  • Hansen AR, Tannock IF, Templeton AJ, Chen X, Evans A, Knox J, Prawira A, Sridhar S, Tan Q, Vera-Badillo F, Wang L, Wouters B, Joshua AM. Pantoprazole affecting Docetaxel resistance pathways via autophagy (PANDORA): Phase II trial of high dose pantoprazole (autophagy inhibitor) with docetaxel in metastatic Castration-Resistant Prostate Cancer (mCRPC). Oncologist. 2019 Apr 5. pii: theoncologist.2018-0621. doi: 10.1634/theoncologist.2018-0621.
  • Rodríguez-Fernández IA, Rodríguez-Romo L, Hernandez-Barajas D, Gonzalez-Conchas GA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE. Adjuvant Radiation Therapy after Radical Nephrectomy in Patients With Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Oncol. 2019 Jul;2(4):448-455. doi: 10.1016/j.euo.2018.10.003.
  • Bojaxhiu B, Templeton AJ, Elicin O, Shelan M, Zaugg K, Walser M, Giger R, Aebersold D, Dal Pra A. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-)radiation. Radiat Oncol. 2018 Nov 6;13(1):216. doi: 10.1186/s13014-018-1159-y.
  • Templeton AJ, Rodríguez Lescure A, Ruíz A, Alba E, Calvo L, Ruíz Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia Marco J, Lluch A, Álvarez I, Casas M; Sánchez-Aragó M, Caballero R, Carrasco E, Amir E, Martin M, Ocaña A. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clin Transl Oncol. 2018 May 15. doi: 10.1007/s12094-018-1885-5.
  • Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018 Nov 1;29(11):2200-2207. doi: 10.1093/annonc/mdy406.
  • Ghatalia P, Pond GR, Templeton AJ, Sonpavde G.  Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. Clin Genitourin Cancer. 2018 Apr;16(2):e277-e287. doi: 10.1016/j.clgc.2017.12.006. 
  • Tibau A, Anguera G, Andrés-Pretel F, Templeton AJ, Seruga B, Barnadas A, Amir E, Ocana A. Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. Oncotarget. 2018 Feb 28;9(19):15061-15067. doi: 10.18632/oncotarget.24589.
  • Tibau A, Molto C, Ocana A, Templeton AJ, Del Carpio LP, Del Paggio JC, Barnadas A, Booth CM, Amir E. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. J Natl Cancer Inst. 2018 May 1;110(5):486-492. doi: 10.1093/jnci/djx232.
  • Baumann M, Dani SU, Dietrich D, Hochstrasser A, Klingbiel D, Mark MT, Riesen WF, Ruhstaller T, Templeton AJ, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. Swiss Med Wkly. 2018 Jan 16;148:w14576. doi: 10.4414/smw.2018.14576.
  • Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir E. Reporting of randomized trials in common cancers in the lay media. Oncology 2018;94:65–71. doi: 10.1159/000484630.
  • Omlin A, Spahn M, Beyer J, Eberli D, Gillessen S, Jochum W, Kueng M, Nitzsche E, Rentsch CA, Roggero E, Schmid H-P, Stenner F, Templeton AJ, Wild D, Wyler S, Zwahlen D, Cathomas R. Medikamentöse Behandlung des metastasierten Prostatakarzinoms – eine interdisziplinäre Empfehlung. Praxis. 2018 Sep;107(19):1043-1051. doi: 10.1024/1661-8157/a003054.
  • Adam R, Diez-Gonzalez L, Ocana A, Seruga A, Amir E, Templeton AJ. Prognostic Role of Telomere Length in Malignancies: A Meta-Analysis and Meta-Regression. Exp Mol Pathol. 2017 May 12. pii: S0014-4800(17)30164-8. doi: 10.1016/j.yexmp.2017.05.010.
  • Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE.  Epidermal Growth Factor Receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. Cancer Treat Rev. 2017 Oct 31;62:1-8. doi: 10.1016/j.ctrv.2017.10.008.
  • Niraula S, Templeton AJ, Vera-Badillo F, Dodd A, Nugent Z, Joshua AM, Tannock IF. Suppression of Bone Turnover Following Zoledronic Acid in Men with Metastatic Castration Resistant Prostate Cancer. Future Science OA 2017 Oct 20
  • Goldvaser H, AlGorashi I, Ribnikar D, Seruga B, Templeton AJ, Ocana A, Amir E. Efficacy of Extended Adjuvant Therapy with Aromatase Inhibitors in Early Breast Cancer among Common Clinicopathologically-defined Subgroups: A Systematic Review and Meta-analysis. Cancer Treat Rev. 2017 Sep;59:46-53. doi: 10.1016/j.ctrv.2017.06.007.
  • Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M.  Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Patients with Non-Small Cell Lung Cancer (NSCLC) treated with Nivolumab. Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024.
  • Goldvaser H, Ribnikar D, Fazelzad R, Seruga B, Templeton AJ, Ocana A, Amir E. Influence of Non-Measurable Disease on Progression-Free Survival in Patients with Metastatic Breast Cancer. Cancer Treat Rev. 2017 Sep;59:46-53. doi: 10.1016/j.ctrv.2017.06.007.
  • Klein SD, Kohler S, Krüerke D, Templeton AJ, Weibel A, Haraldsson E, Nahm M, Wolf U. End-of-life experiences: a survey amongst physicians and nurses in a hospital for anthroposophically extended medicine. Complement Med Res. 2017 Oct 26. doi: 10.1159/000478090.
  • Barnes TA, Amir E, Templeton AJ, Gomez Garcia S, Navarro B, Seruga B, Ocana A. Efficacy, Safety, Tolerability and Price of Newly Approved Drugs in Solid Tumors. Cancer Treat Rev. 2017 May;56:1-7. doi: 10.1016/j.ctrv.2017.03.011.
  • Ethier J-L, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S. Is the Neutrophil-to-Lymphocyte Ratio Prognostic of Survival Outcomes in Gynecologic Cancers? A Systematic Review and Meta-Analysis. Gynecol Oncol. 2017 Feb 17. pii: S0090-8258(17)30147-6. doi: 10.1016/j.ygyno.2017.02.026.
  • Tibau A, Diez-Gonzalez L, Navarro B, Templeton AJ, Seruga B, Pandiella A, Amir E, Ocana A. Impact of availability of companion diagnostics on clinical development of anti-cancer drugs. Mol Diagn Ther. 2017 Feb 28. doi: 10.1007/s40291-017-0267-y. 
  • Kulkarni GS, Hermanns T, Wie Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, S Bashir, Zlotta AR. A Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327.
  • Ethier J-L, Desautels D, Templeton AJ, Shah P, Amir E. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Res. 2017 Jan 5;19(1):2. doi: 10.1186/s13058-016-0794-1.
  • Ocana A, Cristina Nieto-Jiménez C; Pandiella A, Templeton AJ. Neutrophils in Cancer: Prognostic Role and Therapeutic Strategies.  Mol Cancer. 2017 Aug 15;16(1):137. doi: 10.1186/s12943-017-0707-7.  
  • Templeton AJ, Diez Gonzalez L, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, Srikanthan A, Pandiella A, Amir E, Ocana A Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations: A systematic review and meta-regression. PLoS One. 2016 May 5;11(5):e0154789. doi: 10.1371/journal.pone.0154789. eCollection 2016.
  • Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, Broom R, Fay AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, Kanesvaran R, Alimohamed N, Hermanns T, Wells JC, Amir E, Choueiri TK, Heng DYC. Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol. 2016 Feb 25. pii: S0302-2838(16)00211-6. doi: 10.1016/j.eururo.2016.02.033.  
  • Khoja L, Atenafu EG, Ye Q, Templeton AJ, Chappell M, Hogg D, Butler MO, Joshua AM. The full blood count as a biomarker of outcome and toxicity in ipilimumab treated cutaneous metastatic melanoma. Cancer Med. 2016 Oct;5(10):2792-2799. doi: 10.1002/cam4.878.
  • Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SMH, Chan A-W, Ocana A, Templeton AJ, Seruga B, Amir E, Tannock IF. Honorary and Ghost-Authorship in Reports of Randomized Clinical Trials in Oncology. Eur J Cancer. 2016 Oct;66:1-8. doi: 10.1016/j.ejca.2016.06.023. 
  • Sonpavde G, Pond GR, Templeton AJ, Kwon ED, De Bono JS. Impact of single agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2016 Sep 27. doi: 10.1038/pcan.2016.44.
  • Vera-Badillo FE, Marc Napoleone M, Krzyzanowska MK, Alibhai SMH, Chan A-W, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF. Bias in Reporting of Randomized Clinical Trials in Oncology. Eur J Cancer. 2016 Jul;61:29-35. doi: 10.1016/j.ejca.2016.03.066.
  • Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, Sánchez-Corrales V, Templeton AJ, Seruga B, Pandiella A, Amir E. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. Oncotarget. 2016 Mar 16. doi: 10.18632/oncotarget.8118.
  • Ocaña A, Pérez-Peña J, Díez-González L, Sánchez-Corrales V, Templeton A, Seruga B, Amir E, Pandiella A. Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. Breast Cancer Res Treat. 2016 Feb;156(1):1-8. doi: 10.1007/s10549-016-3720-4.
  • Srikanthan A, Vera-Badillo F, Ethier J-L, Goldstein R, Templeton AJ, Ocana A, Seruga B, Amir E. Evolution in the Eligibility Criteria of Randomized Controlled Trials for Systemic Cancer Therapies. Cancer Treat Rev. 2016 Feb;43:67-73. doi: 10.1016/j.ctrv.2015.12.006. 
  • Tibau A, Ocana A, Anguera G, Seruga B, Templeton AJ, Barnadas A, Amir E. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the U.S. Food and Drug Administration. JAMA Oncol. 2016 Mar 3. doi: 10.1001/jamaoncol.2015.6479.
  • Bhindi B, Hermanns T, Wei Y, Yu J, Richard P, Wettstein M, Templeton AJ, Li K, Sridhar S, Jewett M, Fleshner N, Zlotta A, Kulkarni G. Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer. 2016 Jan 19;114(2):207-12. doi: 10.1038/bjc.2015.432.
  • Ocana A, Díez-González L, Templeton AJ, Vera-Badillo F, José Escribano M, Serrano G, Sánchez-Corrales V, Seruga B, Pandiella A, Amir E. Circulating DNA and survival in solid tumors. Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):399-406. doi: 10.1158/1055-9965.EPI-15-0893.
  • Niraula S, Templeton AJ, Vera-Badillo FE, Joshua AM, Sridhar SS, Knox JJ, Cheung PW, Yip PM, Dodd A, Nugent Z, Tannock IF.  Testosterone-Guided Schedule of Androgen Deprivation Therapy as an Alternative to a Fixed Schedule in Management of Prostate Cancer. Prostate. 2016 Feb;76(2):235-42. doi: 10.1002/pros.23117.
  • Tannock IF, Amir E, Booth CM, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F. The relevance of randomized controlled trials to clinical practice. Lancet Oncol. 2016 Dec;17(12):e560-e567. doi: 10.1016/S1470-2045(16)30572-1.  
  • Seruga B, Templeton AJ, Vera Badillo FE, Ocana A, Amir E, Tannock IF. Under-reporting of harm in clinical trials. Lancet Oncol. 2016 May;17(5):e209-19. doi: 10.1016/S1470-2045(16)00152-2.
  • Templeton AJ, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond GR, Tannock IF. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur J Cancer. 2015 Apr;51(6):721-4. doi: 10.1016/j.ejca.2014.12.016.
  • van Soest RJ, Templeton AJ,  Vera-Badillo FE, Mercier F,  Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger MA, Tannock IF, de Wit R. Neutrophil to lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2015 Apr;26(4):743-9. doi: 10.1093/annonc/mdu569.
  • Leibowitz-Amit R, Templeton AJ, Alibhai SM, Knox JJ, Sridhar SS, Tannock IF, Joshua AM. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2015 Jan;6(1):23-8. doi: 10.1016/j.jgo.2014.09.183.
  • Al Hashem H, Al-Mubarak M, Vera-Badillo FE, Templeton AJ, Ocana A, Seruga B, Amir E. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clin Oncol (R Coll Radiol). 2015 Nov 2. pii: S0936-6555(15)00386-6. doi: 10.1016/j.clon.2015.09.010.
  • Ocana A, Ethier J-L, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget. 2015 Nov 24;6(37):39538-49. doi: 10.18632/oncotarget.5946.
  • Turner N, Wong H-L, Templeton AJ, Tripathy S, Rogers TW, Croxford M, Jones I, Sinnathamby M, Desai J, Tie J, Bae S, Christie M, Gibbs P, Tran B. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. Int J Cancer; 2015 Aug 13. doi: 10.1002/ijc.29805.
  • Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E. Association between Androgen Receptor Expression, Ki-67 and the 21-Gene Recurrence Score in Non-metastatic, Lymph node-negative, Estrogen Receptor-positive and HER2-negative Breast Cancer. J Clin Pathol. 2015 Jun 15. pii: jclinpath-2015-203012. doi: 10.1136/jclinpath-2015-203012.
  • Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono J. Baseline Neutrophil-Lymphocyte Ratio (NLR) is Associated with Survival and Response to Treatment with Second-Line Chemotherapy for Advanced Prostate Cancer Independent of Baseline Steroid Use. Ann Oncol. 2015 Apr;26(4):750-5. doi: 10.1093/annonc/mdu587.
  • Tibau A, Bedard PL, Srikanthan A, Ethier J, Vera Badillo FE, Templeton AJ, Ocaña A, Seruga B, Barnadas A, Amir E. Author Financial Conflicts of Interest, Industry Funding and Clinical Practice Guidelines for Anti-Cancer Drugs. J Clin Oncol. 2015 Jan 1;33(1):100-6. doi: 10.1200/JCO.2014.57.8898.
  • Sonpavde G, Pond GR, Templeton AJ, Fandi A, Tombal B, Rosenthal M, Armstrong AJ, Petrylak DP. The association of RECIST changes with survival in patients with metastatic castration resistant prostate cancer receiving docetaxel. Eur Urol. 2015 Oct 20. pii: S0302-2838(15)00978-1. doi: 10.1016/j.eururo.2015.10.008.
  • Templeton AJ, Seruga B. Primum Non Nocere. Ann Oncol. 2015 Oct;26(10):2197-8. doi: 10.1093/annonc/mdv291.
  • Templeton AJ, Diez Gonzalez L, Ace O, Vera-Badillo F, Šeruga B, Jordán J, Amir E, Pandiella A, Ocaña A. Prognostic Relevance of Receptor Tyrosine Kinase Expression in Breast Cancer: A meta-analysis. Cancer Treat Rev. 2014 Oct;40(9):1048-55. doi: 10.1016/j.ctrv.2014.08.003.  
  • Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo MD FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil to lymphocyte ratio. Cancer. 2014 Nov 1;120(21):3346-52. doi: 10.1002/cncr.28890.
  • Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Šeruga B, Ocaña A, Tannock IF, Amir E. Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12. doi: 10.1158/1055-9965.EPI-14-0146.
  • Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124. doi: 10.1093/jnci/dju124.
  • Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz S-F, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder RC, Rochlitz C, von Moos R, Zaman K, Thürlimann BJK, Ruhstaller T. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast. 2014 Jun;23(3):244-9. doi: 10.1016/j.breast.2014.02.005
  • Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, Vera-Badillo F, Attard G, Knox J, Sridhar S, Tannock IF, de Bono JS, Joshua AM. Biomarkers associated with PSA response to abiraterone in men with metastatic castration-resistant prostate cancer. Ann Oncol. 2014 Mar;25(3):657-62. doi: 10.1093/annonc/mdt581.
  • Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton AJ, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. Eur Urol. 2014 Dec 15. pii: S0302-2838(14)01249-4. doi: 10.1016/j.eururo.2014.11.054.
  • Rocha P, Morgan CJ, Templeton AJ, Pond GR, Naik G, Sonpavde G. Prognostic Impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. Oncol Res Treat. 2014;37(12):772-6. doi: 10.1159/000369545.
  • Shao T, Wang L, Templeton AJ, Jang R, Margolis M, Sinaei M, Shoushtari H, Kim TK, McNamara M, Vera-Badillo F, Havill D, Tannock I. Use and Misuse of Waterfall Plots. J Natl Cancer Inst. 2014 Oct 29;106(12). pii: dju331. doi: 10.1093/jnci/dju331
  • Leibowitz-Amit R, Seah J-A, Atenafu EG, Templeton AJ, Vera-Badillo FE, Alimohamed N, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer: A Retrospective Review of the Princess Margaret Experience of (I) low dose abiraterone and (II) Prior Ketoconazole. Eur J Cancer. 2014 Sep;50(14):2399-407. doi: 10.1016/j.ejca.2014.06.004.
  • Leibowitz-Amit R, Alimohamed N, Vera-Badillo FE, Seah J-A, Templeton AJ, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Retretment of Men With Metastatic Castrate-Resistant Prostate Cancer With Abiraterone. Prostate. 2014 Oct;74(14):1462-4. doi: 10.1002/pros.22861.
  • Vera-Badillo FE, Napoleone M, Ocana A, Templeton AJ, Al-Mubarak M, Tannock IF, Amir E. Effect of Multifocality and Multicentricity on Outcome in Early Stage Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Res Treat. 2014 Jul;146(2):235-44. doi: 10.1007/s10549-014-3018-3.
  • Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E. Systemic Therapy for Non-Clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-Analysis. Eur Urol. 2014 May 29. pii: S0302-2838(14)00420-5. doi: 10.1016/j.eururo.2014.05.010.
  • Hermanns T, Bhindi B, Weia Y, Yua J, Bhatt J, Almatar A, Noon AP, Richard P, Jewett MAS, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni GS. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer. 2014 Jul 29;111(3):444-51. doi: 10.1038/bjc.2014.305.
  • Ocana A, Vera-Badillo FE, Al-Mubarak M, Templeton AJ, Seruga B, Sánchez-Corrales V, Pandiella A, Amir A. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One. 2014 Apr 28;9(4):e95219. doi: 10.1371/journal.pone.0095219.
  • Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang S-L, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. Prognostic impact of the neutrophil to lymphocyte ratio in men with metastatic castration resistant prostate cancer. Clin Genitourin Cancer. 2014 Oct;12(5):317-24. doi: 10.1016/j.clgc.2014.03.005.
  • McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Knox JJ. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014 Jun;50(9):1581-9. doi: 10.1016/j.ejca.2014.02.015.
  • McNamara MG, Lwin Z, Jiang H, Templeton AJ, Zadeh G, Berstein M, Chung C, Millar B-A, Laperriere N, Mason WP. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. J Neuro-Oncol. 2014 Mar;117(1):147-52. doi: 10.1007/s11060-014-1366-9.
  • Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, Seruga B, Amir E. Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-analysis. PLoS One. 2014 Feb 20;9(2):e88238. doi: 10.1371/journal.pone.0088238.
  • Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff J, Wild P, Cathomas R, Gillessen S. Metformin in chemotherapy-naïve Castration Resistant Prostate Cancer (CRPC): A multicenter phase II study (SAKK 08/09). Eur Urol. 2014 Sep;66(3):468-74. doi: 10.1016/j.eururo.2013.12.057.
  • Vera-Badillo F, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard P, Al-Mubarak M, Seruga B, Tannock I,  Ocana A, Amir A. Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2014 Jan;106(1):djt319. doi: 10.1093/jnci/djt319.
  • Schlaeppi MR, Templeton AJ. Komplementärmedizin in der Onkologie – Was der Grundversorger wissen sollte. Schweiz Med Forum 2014; 14(37): 689-93
  • Vera-Badillo FE, Ocana A, Templeton AJ, Tibau A, Amir E, Tannock IF. Raising Concern About the American Society of Clinical Oncology Conflict of Interest Policy Amendment. J Clin Oncol. 2014 Oct 1;32(28):3197. doi: 10.1200/JCO.2014.56.2447.
  • Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF. Translating Clinical Trials to Clinical Practice: Outcomes of Men with Metastatic Castration Resistant Prostate Cancer Treated with Docetaxel and Prednisone in and out of Clinical Trials. Ann Oncol. 2013 Dec;24(12):2972-7. doi: 10.1093/annonc/mdt397.
  • Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Droege C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P-Y, Klingbiel D, Gillessen S. Phase 2 Trial of Single Agent Everolimus in Chemotherapy-naïve Patients with Castration Resistant Prostate Cancer (SAKK 08/08). Eur Urol. 2013 Jul;64(1):150-8. doi: 10.1016/j.eururo.2013.03.040.
  • Templeton AJ, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-Sectional Study of Self-Reported Physical Activity, Eating Habits and Use of Complementary Medicine in Breast Cancer Survivors. BMC Cancer. 2013 Mar 25;13:153. doi: 10.1186/1471-2407-13-153.
  • Ocaña A, Vera-Badillo F, Šeruga B, Templeton AJ, Pandiella A, Amir E. HER3 over-expression and survival in solid tumors: A Meta-analysis. J Natl Cancer Inst. 2013 Feb 20;105(4):266-73. doi: 10.1093/jnci/djs501.
  • Vera-Badillo FE, Al-Mubarak M, Templeton AJ, Amir E. Benefit and Harms of New Anti-Cancer Drugs. Curr Oncol Rep. 2013 Jun;15(3):270-5. doi: 10.1007/s11912-013-0303-y.
  • Omlin A, Gillessen S, Templeton A. Neues zur Behandlung des metastasierten Prostatkarzinoms. Swiss Medical Forum 2013; 3(23): 448–452
  • Templeton AJ, Ocaña A, Šeruga B, Vera-Badillo F, Carlsson L, Bedard P, Amir E. Management of small HER2 overexpressing tumours. Breast Cancer Res Treat. 2012 Nov;136(1):289-93. doi: 10.1007/s10549-012-2236-9.
  • Hochstrasser A, Benz G, Joerger M, Templeton A, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event? Chemotherapy. 2012;58(1):84-8. doi: 10.1159/000336131.
  • Kälin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T, Aebersold R, Krek W, Gillessen S. Novel prognostic markers in the serum of patients with castration resistant prostate cancer derived from quantitative analysis of the Pten conditional knockout mouse proteome. Eur Urol. 2011 Dec;60(6):1235-43. doi: 10.1016/j.eururo.2011.06.038.
  • Cima I, Schiess R, Wild P, Kälin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen S, Aebersold R, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3342-7. doi: 10.1073/pnas.1013699108.
  • Joerger M, Templeton A, Koeberle D, Engler H, Riesen W F, Thurlimann B J K. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol. 2011 May;67(5):1137-44. doi: 10.1007/s00280-010-1420-z.
  • Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70. doi: 10.1093/jnci/djq419.
  • Ruhstaller T, Templeton A, Ribi K, Schuller J, Borner M, Thierstein S, von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Koeberle D, Popescu R. Intense Therapy in Patients with Locally Advanced Esophageal Cancer beyond Hope for Surgical Cure: A Prospective, Multicenter Phase II Trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie. 2010;33(5):222-8. doi: 10.1159/000305094.
  • Huober J, Spirig C, Schoch O, Templeton A, Thürlimann B. Interstitial Pneumonitis after Treatment with Bevacizumab and Pegylated Liposomal Doxorubicin in a Patient with Metastatic Breast Cancer.  Chemotherapy. 2010;56(1):69-70. doi: 10.1159/000282286.  
  • Omlin A, Kälin M, Templeton A, Jungi M, Gillessen S, Graf H-J, Rothermundt C. Metastasiertes Prostatakarzinom – Behandlungsmöglichkeiten nach der Hormontherapie. Swiss Medical Forum 2010; 10: 483 – 485
  • Templeton A, Marra G, Valtorta E, Heinimann K, Mueller H, Koeberle D, Gillessen S. Concordant colon tumors in monozygotic twins previously treated for prostate cancer. Fam Cancer. 2009;8(2):167-71. doi: 10.1007/s10689-008-9222-8.
  • Fehr M, Templeton A, Cogliatti S, Aebersold F, Gillessen S, Cathomas R. Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie. 2009 Oct;32(10):586-8. doi: 10.1159/000232584.
  • Fokt RM, Templeton A, Gillessen S, Öhlschlegel C, Schmid HP. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. Urol Int. 2009;83(1):122-4. doi: 10.1159/000224882.
  • Templeton A, Schlegel M, Fleisch F, Rettenmund G, Schöbi B, Henz S, Eich G. Multilumen central venous catheters increase risk for catheter related blood stream infection - prospective surveillance study. Infection. 2008 Aug;36(4):322-7. doi: 10.1007/s15010-008-7314-x.
  • Templeton A, Brändle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008 Apr;19(4):824-5. doi: 10.1093/annonc/mdn047.
  • Templeton A, Hofer S, Töpfer M, Sommacal A, Fretz C, Cerny T, Gillessen S. Extraneural spread of a glioblastoma. Onkologie 2008; 31: 192 - 194
  • Templeton A, Omlin A, Strasser F. An update on the pharmacological management of the cancer anorexia-cachexia-syndrome. European Journal of Palliative Care 2007: 14: 186 - 190
  • Templeton A, Engeler S, Boggian K. Varizellenpneumonie. Swiss Medical Forum 2006; 6: 655
  • Rafeiner P, Templeton A, Vonesch HJ. Swollen leg with blisters. Praxis 2005; 94: 1569 - 1574
  • Templeton A, Vonesch H-J. Intoxikation mit GBL ("liquid ecstasy"). Swiss Medical Forum 2005; 5: 115 - 116

Book Chapters

  • Arnoud J Templeton, Alberto Ocana, Ian F Tannock.  Chapter 11: How to Become a Researcher. Pages 146 – 154, in: ESMO Handbook Oncological Study Publications (2018) ISBN 978-88-941795-5-2
  • By David Dearnaley, Inge van Oort, and Arnoud J Templeton. Chapter 2: Metastatic Prostate Cancer. Pages 7 - 34, in: Summary of Science of Practice – Metastatic Prostate Cancer. Published by Mirrors of Medicine eHIMS bvba, Lier, Belgium (2016), ISBN 978-94-62210127.
  • By Amit Bahl, Arnoud Templeton, Bertrand Tombal (guest editors). Advanced Prostate Cancer. Published by Mirro


Contact Clara Research

St. Clara Forschung AG
Kleinriehenstr. 43
4058 Basel

Tel.: 061 685 85 85

Contact Clara Hospital

Our business hours run from Monday to Friday 8 am to 5 pm. Outside the phone times our reception is manned around the clock.


T: 061 685 85 85